The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Tribulations and future opportunities for artificial intelligence in precision medicine
Open accessAbstract
Upon a diagnosis, the clinical team faces two main questions: what treatment, and at what dose? Clinical trials' results provide the basis for guidance and support for official protocols that clinicians use to base their decisions. However, individuals do not consistently demonstrate the reported response from relevant clinical trials. The decision complexity increases with combination treatments where drugs administered together can interact with each other, which is often the case. Additionally, the individual's response to the treatment varies with the changes in their condition. In practice, the drug and the dose selection depend significantly on the medical protocol and the medical team's experience. As such, the results are inherently varied and often suboptimal. Big data and Artificial Intelligence (AI) approaches have emerged as excellent decision-making tools, but multiple challenges limit their application. AI is a rapidly evolving and dynamic field with the potential to revolutionize various aspects of human life. AI has become increasingly crucial in drug discovery and development. AI enhances decision-making across different disciplines, such as medicinal chemistry, molecular and cell biology, pharmacology, pathology, and clinical practice. In addition to these, AI contributes to patient population selection and stratification. The need for AI in healthcare is evident as it aids in enhancing data accuracy and ensuring the quality care necessary for effective patient treatment. AI is pivotal in improving success rates in clinical practice. The increasing significance of AI in drug discovery, development, and clinical trials is underscored by many scientific publications. Despite the numerous advantages of AI, such as enhancing and advancing Precision Medicine (PM) and remote patient monitoring, unlocking its full potential in healthcare requires addressing fundamental concerns. These concerns include data quality, the lack of well-annotated large datasets, data privacy and safety issues, biases in AI algorithms, legal and ethical challenges, and obstacles related to cost and implementation. Nevertheless, integrating AI in clinical medicine will improve diagnostic accuracy and treatment outcomes, contribute to more efficient healthcare delivery, reduce costs, and facilitate better patient experiences, making healthcare more sustainable. This article reviews AI applications in drug development and clinical practice, making healthcare more sustainable, and highlights concerns and limitations in applying AI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
High-performance medicine: the convergence of human and artificial intelligence
Topol, E. J. (2019) · Nature Medicine · doi:10.1038/s41591-018-0300-7 · Cited by 10,450
The UK Biobank resource with deep phenotyping and genomic data
Bycroft, C., Freeman, C., Petkova, D., Band, G., Elliott, L. T., Sharp, K., Motyer, A., Vukcevic, D., Delaneau, O., O’Connell, J., et al. (2018) · Nature · doi:10.1038/s41586-018-0579-z · Cited by 8,876 · cited 1×
“…enabling the use of PM by establishing data repositories is not restricted to the United States; examples from Biobanks in many countries, such as the UK Biobank, [36], BioBank Japan, [37], and Australian Genomics Health Alliance [38] demonstrate the power of changing attitudes toward PM globally.”
BackgroundWeininger, D. (1988) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci00057a005 · Cited by 7,436 · cited 1×
“Notable observations include GPT-4’s ability to generate valid chemical structures (Simplified Molecular Input Line Entry System, SMILES) output [116], demonstrating GPT-4’s capability to accurately perceive and modify chemical structures.”
BackgroundDissecting racial bias in an algorithm used to manage the health of populations
Obermeyer, Z., Powers, B., Vogeli, C., & Mullainathan, S. (2019) · Science · doi:10.1126/science.aax2342 · Cited by 7,137 · cited 1×
“AI models can be biased, meaning that the performance can depend on patient characteristics like age, gender, or ethnicity [70].”
BackgroundThe potential for artificial intelligence in healthcare
Davenport, T., & Kalakota, R. (2019) · Future Healthcare Journal · doi:10.7861/futurehosp.6-2-94 · Cited by 3,800
Applications of machine learning in drug discovery and development
Vamathevan, J., Clark, D., Czodrowski, P., Dunham, I., Ferran, E., Lee, G., Li, B., Madabhushi, A., Shah, P., Spitzer, M., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0024-5 · Cited by 3,228
Automatic Chemical Design Using a Data-Driven Continuous Representation of Molecules
Gómez-Bombarelli, R., Wei, J. N., Duvenaud, D., Hernández-Lobato, J. M., Sánchez-Lengeling, B., Sheberla, D., Aguilera-Iparraguirre, J., Hirzel, T. D., Adams, R. P., & Aspuru-Guzik, A. (2018) · ACS Central Science · doi:10.1021/acscentsci.7b00572 · Cited by 3,106
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Havel, J. J., Chowell, D., & Chan, T. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0116-x · Cited by 2,286 · cited 1×
“Undoubtedly, AI might benefit healthcare only when the medical community can assess its value and potential opportunities and acknowledge the limitations in treating different diseases [16].”
BackgroundPrecision medicine, AI, and the future of personalized health care
Johnson, K. B., Wei, W., Weeraratne, D., Frisse, M. E., Misulis, K., Rhee, K., Zhao, J., & Snowdon, J. L. (2021) · Clinical and Translational Science · doi:10.1111/cts.12884 · Cited by 1,854
ChatGPT: five priorities for research
van Dis, E. A. M., Bollen, J., Zuidema, W., van Rooij, R., & Bockting, C. L. (2023) · Nature · doi:10.1038/d41586-023-00288-7 · Cited by 1,842 · cited 1×
“As highlighted in recent literature by groups like Has-selgren and Oprea [42] ChatGPT, a conversational AI that has successfully passed the US Medical Licensing Examination, to revolutionize research practices and publishing [114].”
BackgroundArtificial intelligence in drug discovery and development
Paul, D., Sanap, G., Shenoy, S., Kalyane, D., Kalia, K., & Tekade, R. K. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2020.10.010 · Cited by 1,695
Artificial intelligence in surgery: promises and perils
Hashimoto, D. A., Rosman, G., Rus, D., & Meireles, O. R. (2018) · Annals of Surgery · doi:10.1097/sla.0000000000002693 · Cited by 1,468
Artificial intelligence in drug development: Present status and future prospects
Mak, K.-K., & Pichika, M. R. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2018.11.014 · Cited by 1,018
Legal and Ethical Consideration in Artificial Intelligence in Healthcare: Who Takes Responsibility?
Naik, N., Hameed, B. M. Z., Shetty, D. K., Swain, D., Shah, M., Paul, R., Aggarwal, K., Ibrahim, S., Patil, V., Smriti, K., et al. (2022) · Frontiers in Surgery · doi:10.3389/fsurg.2022.862322 · Cited by 931
Rethinking drug design in the artificial intelligence era
Schneider, P., Walters, W. P., Plowright, A. T., Sieroka, N., Listgarten, J., Goodnow, R. A., Fisher, J., Jansen, J. M., Duca, J. S., Rush, T. S., et al. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0050-3 · Cited by 894
Hansen, K., Biegler, F., Ramakrishnan, R., Pronobis, W., von Lilienfeld, O. A., Müller, K.-R., & Tkatchenko, A. (2015) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.5b00831 · Cited by 815
Augmenting large language models with chemistry tools
M. Bran, A., Cox, S., Schilter, O., Baldassari, C., White, A. D., & Schwaller, P. (2024) · Nature Machine Intelligence · doi:10.1038/s42256-024-00832-8 · Cited by 794
The role of AI in drug discovery: challenges, opportunities, and strategies
Blanco-González, A., Cabezón, A., Seco-González, A., Conde-Torres, D., Antelo-Riveiro, P., Piñeiro, Á., & Garcia-Fandino, R. (2023) · Pharmaceuticals · doi:10.3390/ph16060891 · Cited by 690
Deep learning in cancer pathology: a new generation of clinical biomarkers
Echle, A., Rindtorff, N. T., Brinker, T. J., Luedde, T., Pearson, A. T., & Kather, J. N. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01122-x · Cited by 667 · cited 1×
“These studies rely on digital pathology, radiology, and genomic data to optimize the design of combination regimens and determine appropriate dosing of chemotherapy and immunotherapy [58–60].”
MethodArtificial intelligence in COVID-19 drug repurposing
Zhou, Y., Wang, F., Tang, J., Nussinov, R., & Cheng, F. (2020) · The Lancet Digital Health · doi:10.1016/s2589-7500(20)30192-8 · Cited by 636 · cited 1×
“Numerous other examples highlight the capacity of AI-based methods to expedite drug screening and discovery [92] and enhance the development of more effective therapies, drug combinations for drug synergies [93, 94], and drug repurposing [88, 95–103] for various other diseases [104–110].”
BackgroundArtificial Intelligence in Health Care: A Report From the National Academy of Medicine
Matheny, M. E., Whicher, D., & Thadaney Israni, S. (2020) · JAMA · doi:10.1001/jama.2019.21579 · Cited by 628 · cited 1×
“Unfortunately, using AI is not without strings, with social and ethical challenges to security, privacy, and human rights [13–15].”
BackgroundHow artificial intelligence is changing drug discovery
Fleming, N. (2018) · Nature · doi:10.1038/d41586-018-05267-x · Cited by 546 · cited 1×
“Numerous other examples highlight the capacity of AI-based methods to expedite drug screening and discovery [92] and enhance the development of more effective therapies, drug combinations for drug synergies [93, 94], and drug repurposing [88, 95–103] for various other diseases [104–110].”
BackgroundBig data and artificial intelligence modeling for drug discovery
Zhu, H. (2020) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010919-023324 · Cited by 455 · cited 1×
“The intersection of big data and AI in drug discovery continues to attract considerable interest [44].”
BackgroundVatansever, S., Schlessinger, A., Wacker, D., Kaniskan, H. Ü., Jin, J., Zhou, M., & Zhang, B. (2021) · Medicinal Research Reviews · doi:10.1002/med.21764 · Cited by 429
Bender, A., & Cortés-Ciriano, I. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2020.12.009 · Cited by 405
Clinical-Grade Detection of Microsatellite Instability in Colorectal Tumors by Deep Learning
Echle, A., Grabsch, H. I., Quirke, P., van den Brandt, P. A., West, N. P., Hutchins, G. G. A., Heij, L. R., Tan, X., Richman, S. D., Krause, J., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.06.021 · Cited by 376
Therapies for rare diseases: therapeutic modalities, progress and challenges ahead
Tambuyzer, E., Vandendriessche, B., Austin, C. P., Brooks, P. J., Larsson, K., Miller Needleman, K. I., Valentine, J., Davies, K., Groft, S. C., Preti, R., et al. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0049-9 · Cited by 357
The impact of site-specific digital histology signatures on deep learning model accuracy and bias
Howard, F. M., Dolezal, J., Kochanny, S., Schulte, J., Chen, H., Heij, L., Huo, D., Nanda, R., Olopade, O. I., Kather, J. N., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24698-1 · Cited by 330
ZINC-22─A Free Multi-Billion-Scale Database of Tangible Compounds for Ligand Discovery
Tingle, B. I., Tang, K. G., Castanon, M., Gutierrez, J. J., Khurelbaatar, M., Dandarchuluun, C., Moroz, Y. S., & Irwin, J. J. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c01253 · Cited by 314
Artificial intelligence applied to clinical trials: opportunities and challenges
Askin, S., Burkhalter, D., Calado, G., & El Dakrouni, S. (2023) · Health and Technology · doi:10.1007/s12553-023-00738-2 · Cited by 285
Haslam, A., Gill, J., & Prasad, V. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.0423 · Cited by 283
Impact of artificial intelligence on miss rate of colorectal neoplasia
Wallace, M. B., Sharma, P., Bhandari, P., East, J., Antonelli, G., Lorenzetti, R., Vieth, M., Speranza, I., Spadaccini, M., Desai, M., et al. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.03.007 · Cited by 273
Kim, M. O., Coiera, E., & Magrabi, F. (2017) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocw154 · Cited by 263
Artificial Intelligence for Drug Discovery: Are We There Yet?
Hasselgren, C., & Oprea, T. I. (2024) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-040323-040828 · Cited by 236 · cited 4×
“As discussed in the literature, [27, 28, 39–42], AI-based drug discovery and screening alongside laboratory automation could augment human drug design, chemical synthesis, drug screening, biological testing, and decision-making involved in drug discovery and development, potentially overcoming low…”
BackgroundInfluentialPrediction of drug efficacy from transcriptional profiles with deep learning
Zhu, J., Wang, J., Wang, X., Gao, M., Guo, B., Gao, M., Liu, J., Yu, Y., Wang, L., Kong, W., et al. (2021) · Nature Biotechnology · doi:10.1038/s41587-021-00946-z · Cited by 193 · cited 1×
“Additionally, the use of machine learning to pinpoint small-molecule inhibitors of MEK, a potential cancer treatment target, has been documented [82].”
BackgroundAlphaFold, Artificial Intelligence (AI), and Allostery
Nussinov, R., Zhang, M., Liu, Y., & Jang, H. (2022) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.2c04346 · Cited by 190 · cited 1×
“AlphaFold, a powerful algorithm that uses protein sequence data and AI to predict the proteins’ corresponding three-dimensional structures [81] uses protein sequence data and AI to predict the proteins’ corresponding three-dimensional structures which potentially can revolutionize personalized…”
MethodAI in small-molecule drug discovery: a coming wave?
Jayatunga, M. K. P., Xie, W., Ruder, L., Schulze, U., & Meier, C. (2022) · Nature Reviews Drug Discovery · doi:10.1038/d41573-022-00025-1 · Cited by 187
Computational and artificial intelligence-based methods for antibody development
Kim, J., McFee, M., Fang, Q., Abdin, O., & Kim, P. M. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.12.005 · Cited by 178
Bai, Q., Liu, S., Tian, Y., Xu, T., Banegas‐Luna, A. J., Pérez‐Sánchez, H., Huang, J., Liu, H., & Yao, X. (2022) · WIREs Computational Molecular Science · doi:10.1002/wcms.1581 · Cited by 156 · cited 1×
“Numerous other examples highlight the capacity of AI-based methods to expedite drug screening and discovery [92] and enhance the development of more effective therapies, drug combinations for drug synergies [93, 94], and drug repurposing [88, 95–103] for various other diseases [104–110].”
BackgroundToxicity prediction based on artificial intelligence: A multidisciplinary overview
Pérez Santín, E., Rodríguez Solana, R., González García, M., García Suárez, M. D. M., Blanco Díaz, G. D., Cima Cabal, M. D., Moreno Rojas, J. M., & López Sánchez, J. I. (2021) · WIREs Computational Molecular Science · doi:10.1002/wcms.1516 · Cited by 153 · cited 1×
“Significant progress has also been made in preventing the toxicity of potential drug compounds through intensive training using extensive databases of known toxic and non-toxic compounds for using ML [112].”
BackgroundQuality control stress test for deep learning-based diagnostic model in digital pathology
Schömig-Markiefka, B., Pryalukhin, A., Hulla, W., Bychkov, A., Fukuoka, J., Madabhushi, A., Achter, V., Nieroda, L., Büttner, R., Quaas, A., et al. (2021) · Modern Pathology · doi:10.1038/s41379-021-00859-x · Cited by 146
Koromina, M., Pandi, M.-T., & Patrinos, G. P. (2019) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2019.0151 · Cited by 140
Muti, H. S., Heij, L. R., Keller, G., Kohlruss, M., Langer, R., Dislich, B., Cheong, J.-H., Kim, Y.-W., Kim, H., Kook, M.-C., et al. (2021) · The Lancet Digital Health · doi:10.1016/s2589-7500(21)00133-3 · Cited by 126
Guo, L. N., Lee, M. S., Kassamali, B., Mita, C., & Nambudiri, V. E. (2022) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.06.884 · Cited by 122
ChemCrow: Augmenting large-language models with chemistry tools
Bran, A. M., Cox, S., Schilter, O., Baldassari, C., White, A. D., & Schwaller, P. (2023) · arXiv · doi:10.48550/arxiv.2304.05376 · Cited by 122
De Novo Design of New Chemical Entities for SARS-CoV-2 Using Artificial Intelligence
Bung, N., Krishnan, S. R., Bulusu, G., & Roy, A. (2021) · Future Medicinal Chemistry · doi:10.4155/fmc-2020-0262 · Cited by 118
Lv, H., Shi, L., Berkenpas, J. W., Dao, F.-Y., Zulfiqar, H., Ding, H., Zhang, Y., Yang, L., & Cao, R. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab320 · Cited by 107 · cited 1×
“Notably, these AI-powered approaches have significantly reduced the time needed to identify promising drug candidates compared to traditional methods [86– 91].”
BackgroundLi, R., Kumar, A., & Chen, J. H. (2023) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2023.1835 · Cited by 104 · cited 3×
“Li et al. [10] concluded that emerging AI systems could help to reduce the burden of laborious tasks in modern medicine, enabling physicians to devote their time to treating people.”
BackgroundThe Potential Applications of Artificial Intelligence in Drug Discovery and Development
Farghali, H., Kutinová Canová, N., & Arora, M. (2021) · Physiological Research · doi:10.33549/physiolres.934765 · Cited by 72
Artificial Intelligence Technologies for COVID-19 De Novo Drug Design
Floresta, G., Zagni, C., Gentile, D., Patamia, V., & Rescifina, A. (2022) · doi:10.20944/preprints202203.0032.v1 · Cited by 67 · cited 1×
“Notably, these AI-powered approaches have significantly reduced the time needed to identify promising drug candidates compared to traditional methods [86– 91].”
Jang, H. Y., Song, J., Kim, J. H., Lee, H., Kim, I.-W., Moon, B., & Oh, J. M. (2022) · npj Digital Medicine · doi:10.1038/s41746-022-00639-0 · Cited by 63 · cited 1×
“This issue has recently been tackled by an ML algorithm, which accurately predicts the interactions of novel drug pairs [113].”
Dhamodharan, G., & Mohan, C. G. (2022) · Molecular Diversity · doi:10.1007/s11030-021-10282-8 · Cited by 56
Success stories of AI in drug discovery - where do things stand?
Mak, K.-K., Balijepalli, M. K., & Pichika, M. R. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.1985108 · Cited by 51 · cited 1×
“A recent study highlights successful partnerships between AI firms and the pharmaceutical industry in drug discovery and development [121].”
BackgroundAdvancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence
Duran-Frigola, M., Cigler, M., & Winter, G. E. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.2c11098 · Cited by 50
Karki, N., Verma, N., Trozzi, F., Tao, P., Kraka, E., & Zoltowski, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041573 · Cited by 43
Advancing health care via artificial intelligence: From concept to clinic
Sandeep Ganesh, G., Kolusu, A. S., Prasad, K., Samudrala, P. K., & Nemmani, K. V. S. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175320 · Cited by 43
Bentwich, I. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103515 · Cited by 22
Fighting COVID-19 with Artificial Intelligence
Monteleone, S., Kellici, T. F., Southey, M., Bodkin, M. J., & Heifetz, A. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-1787-8_3 · Cited by 17
Cited by
Kim, M., Shin, M., Zhao, Y., Ghosh, M., & Son, Y. (2024) · Small Science · doi:10.1002/smsc.202400280 · Cited by 97
Chehadi, A. C., Pereira de Lima, E., Detregiachi, C. R. P., Santos de Argollo Haber, R., Catharin, V. M. C. S., Fornari Laurindo, L., Engracia Valenti, V., Machado Galhardi, C., Tanaka, M., & Maria Barbalho, S. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27010465 · Cited by 8
Metadata
- Authors
- Carini, C., & Seyhan, A. A.
- Venue
- Journal of Translational Medicine
- Published
- 2024-04-30
- Volume
- 22
- Issue
- 1
- Pages
- 411-411
- ISSN
- 1479-5876 (ISSN-L)
- OpenAlex
- W4396610906
- Cited by
- 173
- References
- 58
- FWCI
- 13.87
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.